Arvinas to Present at Upcoming Investor Conferences
02 mai 2024 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
29 avr. 2024 08h19 HE
|
Biomerica, Inc.
Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect™ is a simple FDA cleared 2-minute at-home test that detects early warning...
Promising perspectives for the application of SDS Optic’s inPROBE technology platform for protein expression determination
25 avr. 2024 08h00 HE
|
SDS Optic S.A.
SDS Optic's positive results from the Part I Clinical Trial of the novel optic fiber probe, inPROBE®, in vivo real-time molecular diagnostic technology.
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
24 avr. 2024 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Breast Cancer Market To Reach USD 4.3 Billion By 2032, Says DataHorizzon Research
23 avr. 2024 05h40 HE
|
DataHorizzon Research
Fort Collins, Colorado, April 23, 2024 (GLOBE NEWSWIRE) -- The growing prevalence of breast cancer drives the need for diagnostics in the forecast period. The prevalence of breast cancer...
Global Portable Ultrasound Market Analysis Report 2024-2031: Use of Artificial Intelligence in Portable Ultrasound Devices and Emergence of Wearable Ultrasound Devices Gaining Momentum
18 avr. 2024 07h23 HE
|
Research and Markets
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Portable Ultrasound Market by Product (POCUS, Handheld Ultrasound, Transducer, Gels), Technology (2D, 3D, 4D, Doppler), Display, Application (Breast...
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
15 avr. 2024 09h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
RadNet Teams Up with Basketball Icon Sheryl Swoopes to Promote Healthcare Equity and Access
12 avr. 2024 06h00 HE
|
RadNet, Inc.
RadNet Teams Up with Basketball Icon Sheryl Swoopes to Promote Healthcare Equity and Access.
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
11 avr. 2024 07h00 HE
|
Arvinas Inc.
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01...
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
28 mars 2024 08h30 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer